Merck Blocked In Adding CV Claim For Januvia, May Fall Behind Victoza
Executive Summary
Merck got a complete response letter from FDA on a cardiovascular risk-reduction claim for the DPP-4 inhibitor based on TECOS trial data. This places Januvia/Janumet behind Jardiance, which already has a CV safety label claim, and Victoza, which awaits an FDA decision on a supplemental NDA filed last October.
You may also be interested in...
Diabetes Drug CV Outcomes Trials May Be Needed For Market Success But Not Approval, US FDA Panel Says
Longer, broader premarketing trials should replace the requirement for dedicated outcomes trials to demonstrate CV safety, but competitive pressure may drive sponsors to voluntarily conduct outcomes studies to demonstrate CV benefit, FDA advisory committee members said.
Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response
The latest drug development news and highlights from our FDA Performance Tracker.
Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?
The first large real-world evidence study has found SGLT2 inhibitors cut the rate of hospitalizations for heart failure and all-cause mortality in patients at low risk of cardiovascular events, but the results of CV outcomes studies are awaited to confirm the findings.